Cargando…

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

BACKGROUND: The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through fibroblast-directed upregulation of TGFβ signalling. We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturbation in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derrett-Smith, Emma, Clark, Kristina E. N., Shiwen, Xu, Abraham, David J., Hoyles, Rachel K., Lacombe, Olivier, Broqua, Pierre, Junien, Jean Louis, Konstantinova, Irena, Ong, Voon H., Denton, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419933/ https://www.ncbi.nlm.nih.gov/pubmed/34488870 http://dx.doi.org/10.1186/s13075-021-02592-x

Ejemplares similares

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2016)

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
por: Wettstein, Guillaume, et al.
Publicado: (2017)

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
por: Kamata, Shotaro, et al.
Publicado: (2023)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
por: Møllerhøj, Mathias B., et al.
Publicado: (2022)

In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
por: He, B. K., et al.
Publicado: (2012)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome
por: Huang, Yan, et al.
Publicado: (2017)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL
por: Lundåsen, Thomas, et al.
Publicado: (2020)

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models
por: Entchev, Eugeni, et al.
Publicado: (2020)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Fish Oil and the Pan-PPAR Agonist Tetradecylthioacetic Acid Affect the Amino Acid and Carnitine Metabolism in Rats
por: Bjørndal, Bodil, et al.
Publicado: (2013)

Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures
por: Oyama, Takuji, et al.
Publicado: (2009)

Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate
por: Glänzel, Nícolas Manzke, et al.
Publicado: (2023)

Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma
por: Derrett-Smith, Emma C, et al.
Publicado: (2010)

Role of an Indole-Thiazolidine Molecule PPAR Pan-Agonist and COX Inhibitor on Inflammation and Microcirculatory Damage in Acute Gastric Lesions
por: Santin, José Roberto, et al.
Publicado: (2013)

Novel PPAR Pan Agonist, ZBH Ameliorates Hyperlipidemia and Insulin Resistance in High Fat Diet Induced Hyperlipidemic Hamster
por: Chen, Wei, et al.
Publicado: (2014)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

PPAR Pan Agonist MHY2013 Alleviates Renal Fibrosis in a Mouse Model by Reducing Fibroblast Activation and Epithelial Inflammation
por: Son, Minjung, et al.
Publicado: (2023)

Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis
por: Spierings, Julia, et al.
Publicado: (2021)

Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators
por: Adeghate, Ernest, et al.
Publicado: (2011)

Metabolomics dataset of PPAR-pan treated rat liver
por: Ament, Zsuzsanna, et al.
Publicado: (2016)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione
por: Garcia, Giani M., et al.
Publicado: (2021)

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
por: Clark, Kristina Elizabeth Neergaard, et al.
Publicado: (2023)

Cannabinoids: A New Group of Agonists of PPARs
por: Sun, Yan, et al.
Publicado: (2007)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

AMPK-Dependent Metabolic Regulation by PPAR Agonists
por: Lee, Woo Hyung, et al.
Publicado: (2010)

PPAR Agonists and Metabolic Syndrome: An Established Role?
por: Botta, Margherita, et al.
Publicado: (2018)

PPAR Agonists for the Prevention and Treatment of Lung Cancer
por: Lakshmi, Sowmya P., et al.
Publicado: (2017)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer
por: Huang, Runzhi, et al.
Publicado: (2020)

Children With PANS May Manifest POTS
por: Chan, Avis, et al.
Publicado: (2022)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qcjosa1fvlg54u1uddii4gq64b